Welcome to our dedicated page for Henry Schein SEC filings (Ticker: HSIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Henry Schein, Inc. (NASDAQ: HSIC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a FORTUNE 500 and S&P 500® health care solutions company listed on the Nasdaq Global Select Market, Henry Schein uses its filings to report financial results, governance changes, and other material events relevant to shareholders and analysts.
Henry Schein’s current reports on Form 8-K offer timely updates on topics such as quarterly and year-to-date financial performance, leadership transitions, and key corporate announcements. For example, recent 8-K filings have furnished press releases reporting financial results for specific quarters and have disclosed changes in senior leadership, including the planned retirement of the Chief Executive Officer from that role and related succession planning.
In addition to 8-Ks, investors typically look to Henry Schein’s annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on its Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. These periodic reports, referenced in company news releases, contain discussions of operations, financial condition, risk factors, and litigation matters, as well as commentary on strategic initiatives and partnerships such as the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P.
Stock Titan enhances these filings with AI-powered summaries that help explain complex disclosures in clear language. Instead of reading entire documents, users can review concise explanations of key points, including segment performance, risk factor highlights, and notable changes in capital allocation or governance. Real-time updates from the EDGAR system mean that new Henry Schein filings, such as 8-Ks reporting financial results or leadership changes, appear promptly on this page.
For those tracking insider activity and executive arrangements, Form 4 and 8-K disclosures relating to departures, appointments, and compensatory arrangements provide additional context on management and board-level decisions. By combining raw filings with AI-generated insights, this page helps investors, researchers, and health care market participants interpret Henry Schein’s regulatory reporting more efficiently.
Henry Schein Inc. director Reed Vaughn Tuckson reported an equity award from the company. On March 6, 2026, he acquired 2,577 shares of common stock at a stated price of $0.00 per share, described as a grant, award, or other acquisition.
The award was granted under Henry Schein’s 2023 Non-Employee Director Stock Incentive Plan. According to the footnote, the restricted stock units generally vest after a 12‑month cliff period, subject to certain exceptions and to his continued service to the company. Following this grant, he directly owned 12,520 shares of common stock.
SHEARES BRADLEY T reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein Inc. director Bradley T. Sheares received an equity award of 2,577 shares of common stock on March 6, 2026. The grant was made at no cash cost to him under the company’s 2023 Non-Employee Director Stock Incentive Plan.
According to the terms, these restricted stock units vest after a 12-month cliff period, contingent on his continued service to Henry Schein. Following this award, he beneficially owns 47,623 shares of the company’s common stock directly.
Henry Schein Inc. director Scott Philip Serota reported an equity award in the company’s common stock. He acquired 2,577 shares on a grant or award basis at $0.00 per share, bringing his directly held stake to 10,790 shares.
The award was granted under Henry Schein’s 2023 Non-Employee Director Stock Incentive Plan. According to the terms, these restricted stock units generally vest after a 12‑month cliff period, conditioned on the passage of time and his continued service to the company.
Separately, an additional 1,000 shares are reported as held indirectly by the Serota Family Trust, for which Mr. Serota and his wife serve as both trustees and beneficiaries.
Margulies Anne H. reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein Inc. director Anne H. Margulies reported an equity award of 2,577 shares of common stock on March 6, 2026. The award was granted at no cash cost to her as a stock-based grant.
The grant was made under Henry Schein’s 2023 Non-Employee Director Stock Incentive Plan as restricted stock units that vest after a 12‑month cliff period, subject to her continued board service. Following this award, her directly held common stock totaled 23,153 shares.
Henry Schein Inc. director Philip A. Laskawy reported an equity award from the company. On March 6, 2026, he acquired 2,577 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share.
The award was granted under Henry Schein’s 2023 Non-Employee Director Stock Incentive Plan. These restricted stock units are scheduled to vest after a 12‑month cliff period, subject to limited exceptions and his continued service to the company. Following this grant, he holds 24,538 shares directly.
Henry Schein Inc. director Kurt P. Kuehn reported an equity award. On March 6, 2026, he acquired 2,577 shares of common stock at a stated price of $0.00 per share through a grant under the company’s 2023 Non-Employee Director Stock Incentive Plan.
According to the award terms, these restricted stock units are subject to 12‑month cliff vesting and require his continued service with Henry Schein during that period. Following this grant, Kuehn’s directly held position increased to 18,264 shares of common stock.
HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein Inc. director Robert J. Hombach reported an equity award of 2,577 shares of common stock on March 6, 2026. These shares were granted under the company’s 2023 Non-Employee Director Stock Incentive Plan at no purchase price, increasing his directly held stake to 5,421 shares.
According to the award terms, the restricted stock units generally vest after a 12‑month cliff period, provided Mr. Hombach continues to perform services for Henry Schein. This filing reflects routine director compensation in the form of stock-based incentives.
HERRING JOSEPH L reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein Inc. director Joseph L. Herring received an equity award of 2,577 shares of common stock at a stated price of $0.00 per share. The grant was made under the company’s 2023 Non-Employee Director Stock Incentive Plan and is structured as restricted stock units.
These restricted stock units are subject to 12-month cliff vesting and require Mr. Herring’s continued service with the company for vesting to occur, subject to certain exceptions. Following this award, his directly held position increased to 30,325 shares of Henry Schein common stock.
Faig Carole T reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein director Carole T. Faig received an equity grant from the company. She was awarded 2,577 restricted stock units relating to common stock at a stated price of $0.00 per share as a grant or award.
According to the grant terms, these restricted stock units were issued under Henry Schein's 2023 Non-Employee Director Stock Incentive Plan and generally vest after a 12‑month cliff period, conditioned on her continued service to the company. Following this award, her directly held common stock-related holdings total 8,025 shares.
Henry Schein director Deborah Derby reported an equity award of 2,577 shares of common stock on March 6, 2026. The shares were acquired at a stated price of $0.00 per share as a grant under the company’s 2023 Non-Employee Director Stock Incentive Plan.
According to a footnote, the award consists of restricted stock units that generally vest after a 12-month cliff period, subject to certain exceptions and Ms. Derby’s continued service to Henry Schein. Following this grant, she directly holds a total of 15,093 shares and is also reported as indirect owner, as trustee, of 760 shares held in a trust for her benefit.